Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

Risultato della ricerca: Article

16 Citazioni (Scopus)

Abstract

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies were initially developed in order to avoid the cytotoxic effects of chemotherapy on healthy tissues. However antibodies have not yet replaced chemotherapy agents, since the combination of both kinds of drugs have usually appeared to achieve higher benefit compared with chemotherapy alone. The research for the development of new monoclonal antibodies aims to identify further targets and to provide innovative antibody constructs.
Lingua originaleEnglish
pagine (da-a)1433-1445
Numero di pagine13
RivistaExpert Opinion on Biological Therapy
Volume11
Stato di pubblicazionePublished - 2011

Fingerprint

Immunoglobulin Fragments
Chemotherapy
Tumors
Monoclonal Antibodies
Antibodies
Drug Therapy
Neoplasms
Neoplasm Antibodies
Expert Testimony
Therapeutics
Terminology
Tissue
Growth
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cita questo

@article{06cd44a36b2548fe9d3b49acf1417709,
title = "Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors",
abstract = "Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies were initially developed in order to avoid the cytotoxic effects of chemotherapy on healthy tissues. However antibodies have not yet replaced chemotherapy agents, since the combination of both kinds of drugs have usually appeared to achieve higher benefit compared with chemotherapy alone. The research for the development of new monoclonal antibodies aims to identify further targets and to provide innovative antibody constructs.",
keywords = "Anti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodies; Animals; Antibodies, Monoclonal; Humans; Immunoglobulin Fragments; Immunotherapy; Neoplasm Proteins; Neoplasms; Treatment Outcome; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science",
author = "Gaspare Gulotta and Antonio Russo and Viviana Bazan and {Di Fede}, Gaetana and Gianfranco Cocorullo and Sergio Rizzo and Giuseppe Bronte and {Rolfo Cervetto}, Christian",
year = "2011",
language = "English",
volume = "11",
pages = "1433--1445",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

AU - Gulotta, Gaspare

AU - Russo, Antonio

AU - Bazan, Viviana

AU - Di Fede, Gaetana

AU - Cocorullo, Gianfranco

AU - Rizzo, Sergio

AU - Bronte, Giuseppe

AU - Rolfo Cervetto, Christian

PY - 2011

Y1 - 2011

N2 - Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies were initially developed in order to avoid the cytotoxic effects of chemotherapy on healthy tissues. However antibodies have not yet replaced chemotherapy agents, since the combination of both kinds of drugs have usually appeared to achieve higher benefit compared with chemotherapy alone. The research for the development of new monoclonal antibodies aims to identify further targets and to provide innovative antibody constructs.

AB - Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies were initially developed in order to avoid the cytotoxic effects of chemotherapy on healthy tissues. However antibodies have not yet replaced chemotherapy agents, since the combination of both kinds of drugs have usually appeared to achieve higher benefit compared with chemotherapy alone. The research for the development of new monoclonal antibodies aims to identify further targets and to provide innovative antibody constructs.

KW - Anti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodies; Animals; Antibodies, Monoclonal; Humans; Immunoglobulin Fragments; Immunotherapy; Neoplasm Proteins; Neoplasms; Treatment Outcome; Pharmacology; Clinical Biochemistry; Drug Discov

UR - http://hdl.handle.net/10447/77399

M3 - Article

VL - 11

SP - 1433

EP - 1445

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -